GMED moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 65%.
The 10-day RSI Indicator for GMED moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 20 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMED as a result. In 48 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for GMED turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 26 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
The 10-day moving average for GMED crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 203 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
GMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 121 of 211 cases where GMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.000) is normal, around the industry mean (4.142). P/E Ratio (17.897) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. GMED’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SNWV saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 128 similar instances where the indicator turned negative. In 123 of the 128 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SNWV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 65 similar instances when the indicator turned negative. In 63 of the 65 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SNWV moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SNWV crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNWV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +15.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNWV advanced for three days, in 160 of 195 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNWV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 77 of 83 cases where SNWV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.760) is normal, around the industry mean (4.142). P/E Ratio (1.230) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.873) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SNWV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNWV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
GMED | SNWV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 65 | 100 | |
PRICE GROWTH RATING 1..100 | 73 | 97 | |
P/E GROWTH RATING 1..100 | 83 | 97 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNWV's Valuation (49) in the null industry is in the same range as GMED (73) in the Medical Specialties industry. This means that SNWV’s stock grew similarly to GMED’s over the last 12 months.
SNWV's Profit vs Risk Rating (100) in the null industry is in the same range as GMED (100) in the Medical Specialties industry. This means that SNWV’s stock grew similarly to GMED’s over the last 12 months.
GMED's SMR Rating (65) in the Medical Specialties industry is somewhat better than the same rating for SNWV (100) in the null industry. This means that GMED’s stock grew somewhat faster than SNWV’s over the last 12 months.
GMED's Price Growth Rating (73) in the Medical Specialties industry is in the same range as SNWV (97) in the null industry. This means that GMED’s stock grew similarly to SNWV’s over the last 12 months.
GMED's P/E Growth Rating (83) in the Medical Specialties industry is in the same range as SNWV (97) in the null industry. This means that GMED’s stock grew similarly to SNWV’s over the last 12 months.
| GMED | SNWV | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 59% | 3 days ago 75% |
| Stochastic ODDS (%) | 3 days ago 72% | 3 days ago 78% |
| Momentum ODDS (%) | 3 days ago 53% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 52% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 58% | 3 days ago 90% |
| TrendMonth ODDS (%) | 3 days ago 59% | 3 days ago 90% |
| Advances ODDS (%) | 19 days ago 66% | 20 days ago 82% |
| Declines ODDS (%) | 3 days ago 57% | 3 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 62% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 57% | 3 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMED’s FA Score shows that 0 FA rating(s) are green while SNWV’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMED’s TA Score shows that 4 TA indicator(s) are bullish while SNWV’s TA Score has 5 bullish TA indicator(s).
GMED (@Medical/Nursing Services) experienced а -7.28% price change this week, while SNWV (@Medical/Nursing Services) price change was -17.58% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -11.44%. For the same industry, the average monthly price growth was -15.18%, and the average quarterly price growth was -18.29%.
GMED is expected to report earnings on Feb 23, 2027.
SNWV is expected to report earnings on Mar 19, 2027.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, GMED has been loosely correlated with ZBH. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then ZBH could also see price increases.
| Ticker / NAME | Correlation To GMED | 1D Price Change % | ||
|---|---|---|---|---|
| GMED | 100% | -2.49% | ||
| ZBH - GMED | 62% Loosely correlated | -0.36% | ||
| SYK - GMED | 62% Loosely correlated | -0.98% | ||
| AORT - GMED | 57% Loosely correlated | -2.00% | ||
| MDT - GMED | 55% Loosely correlated | -0.67% | ||
| STE - GMED | 55% Loosely correlated | +0.39% | ||
More | ||||
A.I.dvisor tells us that SNWV and BIAF have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SNWV and BIAF's prices will move in lockstep.
| Ticker / NAME | Correlation To SNWV | 1D Price Change % | ||
|---|---|---|---|---|
| SNWV | 100% | -5.66% | ||
| BIAF - SNWV | 32% Poorly correlated | -10.81% | ||
| VMD - SNWV | 28% Poorly correlated | -1.05% | ||
| MDT - SNWV | 26% Poorly correlated | -0.67% | ||
| SENS - SNWV | 24% Poorly correlated | -9.94% | ||
| GMED - SNWV | 24% Poorly correlated | -2.49% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CMDT | 28.91 | -0.12 | -0.41% |
| PIMCO Commodity and Bond Strategy Active ETF (CMDT) | |||
| OPP | 6.69 | -0.03 | -0.45% |
| RiverNorth/DoubleLine Strategic Opportunity Fund | |||
| DLMY | 28.81 | -0.73 | -2.49% |
| FT Vest U.S. Equity Dual Directional Buffer ETF - May (DLMY) | |||
| GRW | 28.82 | -0.89 | -2.99% |
| TCW Durable Growth ETF (GRW) | |||
| IWV | 392.77 | -13.90 | -3.42% |
| iShares Russell 3000 ETF (IWV) | |||